@saibolla/ada 0.1.2

package/skills/clinical-decision-support/assets/example_gbm_cohort.md

@@ -0,0 +1,208 @@
+# Example: GBM Molecular Subtype Cohort Analysis
+
+## Clinical Context
+
+This example demonstrates a patient cohort analysis stratified by molecular biomarkers, similar to the GBM Mesenchymal-Immune-Active cluster analysis provided as reference.
+
+## Cohort Overview
+
+**Disease**: Glioblastoma (GBM), IDH-wild-type
+
+**Study Population**: n=60 patients with newly diagnosed GBM treated with standard Stupp protocol (temozolomide + radiation → adjuvant temozolomide)
+
+**Molecular Classification**: Verhaak 2010 subtypes with immune signature refinement
+- **Group A**: Mesenchymal-Immune-Active subtype (n=18, 30%)
+- **Group B**: Other molecular subtypes (Proneural, Classical, Neural) (n=42, 70%)
+
+**Study Period**: January 2019 - December 2022
+
+**Data Source**: Single academic medical center, retrospective cohort analysis
+
+## Biomarker Classification
+
+### Mesenchymal-Immune-Active Subtype Characteristics
+
+**Molecular Features**:
+- NF1 alterations (mutations or deletions): 72% (13/18)
+- High YKL-40 (CHI3L1) expression: 100% (18/18, median z-score +2.8)
+- Immune gene signature: Elevated (median ESTIMATE immune score +1250)
+- CD163+ macrophage infiltration: High density (median 195 cells/mm², range 120-340)
+- MES (mesenchymal) signature score: >0.5 (all patients)
+
+**Clinical Characteristics**:
+- Median age: 64 years (range 42-76)
+- Male: 61% (11/18)
+- Tumor location: Temporal lobe predominant (55%)
+- Multifocal disease: 33% (6/18) - higher than overall cohort
+
+### Comparison Groups (Other Subtypes)
+
+**Molecular Features**:
+- Proneural: n=15 (25%) - PDGFRA amplification, younger age
+- Classical: n=18 (30%) - EGFR amplification, chromosome 7+/10-
+- Neural: n=9 (15%) - neuronal markers, may include normal tissue
+
+## Treatment Outcomes
+
+### Response Assessment (RANO Criteria)
+
+**Objective Response Rate** (after chemoradiation, ~3 months):
+- Mesenchymal-Immune-Active: 6/18 (33%) - CR 0, PR 6  
+- Other subtypes: 18/42 (43%) - CR 1, PR 17
+- p = 0.48 (Fisher's exact)
+
+**Interpretation**: No significant difference in initial response rates
+
+### Survival Outcomes
+
+**Progression-Free Survival (PFS)**:
+- Mesenchymal-Immune-Active: Median 7.2 months (95% CI 5.8-9.1)
+- Other subtypes: Median 9.5 months (95% CI 8.1-11.3)
+- Hazard Ratio: 1.58 (95% CI 0.89-2.81), p = 0.12
+- 6-month PFS rate: 61% vs 74%
+
+**Overall Survival (OS)**:
+- Mesenchymal-Immune-Active: Median 12.8 months (95% CI 10.2-15.4)
+- Other subtypes: Median 16.3 months (95% CI 14.7-18.9)
+- Hazard Ratio: 1.72 (95% CI 0.95-3.11), p = 0.073
+- 12-month OS rate: 55% vs 68%
+- 24-month OS rate: 17% vs 31%
+
+**Interpretation**: Trend toward worse survival in mesenchymal-immune-active subtype, not reaching statistical significance in this cohort size
+
+### Response to Bevacizumab at Recurrence
+
+**Subset Analysis** (patients receiving bevacizumab at first recurrence, n=35):
+- Mesenchymal-Immune-Active: n=12
+  - ORR: 58% (7/12)
+  - Median PFS2 (from bevacizumab start): 6.8 months
+- Other subtypes: n=23
+  - ORR: 35% (8/23)
+  - Median PFS2: 4.2 months
+- p = 0.19 (Fisher's exact for ORR)
+- HR for PFS2: 0.62 (95% CI 0.29-1.32), p = 0.21
+
+**Interpretation**: Exploratory finding suggesting enhanced benefit from bevacizumab in mesenchymal-immune-active subtype (not statistically significant with small sample)
+
+## Safety Profile
+
+**Treatment-Related Adverse Events** (Temozolomide):
+
+No significant differences in toxicity between molecular subtypes:
+- Lymphopenia (any grade): 89% vs 86%, p = 0.77
+- Thrombocytopenia (grade 3-4): 22% vs 19%, p = 0.79
+- Fatigue (any grade): 94% vs 90%, p = 0.60
+- Treatment discontinuation: 17% vs 14%, p = 0.77
+
+## Clinical Implications
+
+### Treatment Recommendations
+
+**For Mesenchymal-Immune-Active GBM**:
+
+1. **First-Line**: Standard Stupp protocol (no change based on subtype)
+   - Evidence: No proven benefit for alternative first-line strategies
+   - GRADE: 1A (strong recommendation, high-quality evidence)
+
+2. **At Recurrence - Consider Bevacizumab Earlier**:
+   - Rationale: Exploratory data suggesting enhanced anti-angiogenic response
+   - Evidence: Mesenchymal GBM has high VEGF expression, angiogenic phenotype
+   - GRADE: 2C (conditional recommendation, low-quality evidence from subset)
+
+3. **Clinical Trial Enrollment - Immunotherapy Combinations**:
+   - Rationale: High immune cell infiltration may predict immunotherapy benefit
+   - Targets: PD-1/PD-L1 blockade ± anti-CTLA-4 or anti-angiogenic agents
+   - Evidence: Ongoing trials (CheckMate-498, CheckMate-548 showed negative results, but did not select for immune-active)
+   - GRADE: R (research recommendation)
+
+**For Other GBM Subtypes**:
+- Standard treatment per NCCN guidelines
+- Consider tumor treating fields (Optune) after radiation completion
+- Clinical trials based on specific molecular features (EGFR amplification → EGFR inhibitor trials)
+
+### Prognostic Information
+
+**Counseling Patients**:
+- Mesenchymal-immune-active subtype associated with trend toward shorter survival (12.8 vs 16.3 months)
+- Not definitive due to small sample size and confidence intervals overlapping
+- Prospective validation needed
+- Should not alter standard first-line treatment
+
+## Study Limitations
+
+1. **Small Sample Size**: n=18 in mesenchymal-immune-active group limits statistical power
+2. **Retrospective Design**: Potential selection bias, unmeasured confounders
+3. **Single Institution**: May not generalize to other populations
+4. **Heterogeneous Recurrence Treatment**: Not all patients received bevacizumab; treatment selection bias
+5. **Molecular Classification**: Based on bulk tumor RNA-seq; intratumoral heterogeneity not captured
+6. **No Central Pathology Review**: Molecular classification performed locally
+
+## Future Directions
+
+1. **Prospective Validation**: Confirm survival differences in independent cohort (n>100 per group for adequate power)
+2. **Biomarker Testing**: Develop clinically feasible assay for mesenchymal-immune subtype identification
+3. **Clinical Trial Design**: Immunotherapy combinations targeting mesenchymal-immune-active GBM specifically
+4. **Mechanistic Studies**: Investigate why mesenchymal-immune GBM may respond better to bevacizumab
+5. **Longitudinal Analysis**: Track molecular subtype evolution over treatment course
+
+## Data Presentation Example
+
+### Baseline Characteristics Table
+
+```
+Characteristic                    Mesenchymal-IA (n=18)  Other (n=42)  p-value
+Age, years (median [IQR])         64 [56-71]            61 [53-68]    0.42
+Sex, n (%)
+  Male                            11 (61%)              24 (57%)      0.78
+  Female                          7 (39%)               18 (43%)
+ECOG PS, n (%)
+  0-1                             15 (83%)              37 (88%)      0.63
+  2                               3 (17%)               5 (12%)
+Tumor location
+  Frontal                         4 (22%)               15 (36%)      0.35
+  Temporal                        10 (56%)              16 (38%)
+  Parietal/Occipital              4 (22%)               11 (26%)
+Extent of resection
+  Gross total                     8 (44%)               22 (52%)      0.58
+  Subtotal                        10 (56%)              20 (48%)
+MGMT promoter methylated          5 (28%)               18 (43%)      0.27
+```
+
+### Survival Outcomes Summary
+
+```
+Endpoint                          Mesenchymal-IA        Other         HR (95% CI)        p-value
+Median PFS, months (95% CI)       7.2 (5.8-9.1)        9.5 (8.1-11.3) 1.58 (0.89-2.81)   0.12
+6-month PFS rate                  61%                  74%
+Median OS, months (95% CI)        12.8 (10.2-15.4)     16.3 (14.7-18.9) 1.72 (0.95-3.11) 0.073
+12-month OS rate                  55%                  68%
+24-month OS rate                  17%                  31%
+```
+
+## Key Takeaways
+
+1. **Molecular heterogeneity exists** in GBM with distinct subtypes
+2. **Mesenchymal-immune-active subtype** characterized by NF1 alterations, immune infiltration
+3. **Trend toward worse prognosis** but not statistically significant (power limitations)
+4. **Potential bevacizumab benefit** hypothesis-generating, requires prospective validation
+5. **Immunotherapy target**: High immune infiltration rational for checkpoint inhibitor trials
+6. **Clinical implementation pending**: Need prospective validation before routine subtyping
+
+## References
+
+1. Verhaak RG, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98-110.
+2. Wang Q, et al. Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. Cancer Cell. 2017;32(1):42-56.
+3. Stupp R, et al. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. NEJM. 2005;352(10):987-996.
+4. Gilbert MR, et al. Bevacizumab for Newly Diagnosed Glioblastoma. NEJM. 2014;370(8):699-708.
+5. NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers. Version 1.2024.
+
+---
+
+**This example demonstrates**:
+- Biomarker-based stratification methodology
+- Outcome reporting with appropriate statistics
+- Clinical contextualization of findings
+- Evidence-based recommendations with grading
+- Transparent limitation discussion
+- Structure suitable for pharmaceutical/clinical research documentation
+

package/skills/clinical-decision-support/assets/recommendation_strength_guide.md

@@ -0,0 +1,328 @@
+# Recommendation Strength Guide
+
+## GRADE Framework for Clinical Recommendations
+
+### Components of a Recommendation
+
+Every clinical recommendation should address:
+
+1. **Population**: Who should receive the intervention?
+2. **Intervention**: What specific treatment/action?
+3. **Comparator**: Compared to what alternative?
+4. **Outcome**: What are the expected results?
+5. **Strength**: How strong is the recommendation?
+6. **Quality of Evidence**: How confident are we in the evidence?
+
+### Recommendation Strength (Grade 1 vs Grade 2)
+
+#### Strong Recommendation (Grade 1)
+
+**When to Use**:
+- Desirable effects clearly outweigh undesirable effects (or vice versa)
+- High or moderate quality evidence
+- Values and preferences: Little variability expected
+- Resource implications: Cost-effective or cost considerations minor
+
+**Wording**: "We recommend..." or "Clinicians should..."
+
+**Implications**:
+- Most patients should receive the recommended intervention
+- Adherence to recommendation could be a quality indicator
+- Policy-makers can adapt as performance measure
+
+**Examples**:
+
+```
+STRONG RECOMMENDATION FOR (Grade 1):
+
+"We recommend osimertinib 80 mg daily as first-line therapy for adults with 
+advanced NSCLC harboring EGFR exon 19 deletion or L858R mutation (Strong 
+recommendation, High-quality evidence - GRADE 1A)."
+
+Rationale:
+- Large PFS benefit: 18.9 vs 10.2 months (HR 0.46, p<0.001)
+- OS benefit: 38.6 vs 31.8 months (HR 0.80, p=0.046)  
+- Better tolerability: Lower grade 3-4 AEs
+- Evidence: High-quality (large RCT, low risk of bias)
+- Benefits clearly outweigh harms
+```
+
+```
+STRONG RECOMMENDATION AGAINST (Grade 1):
+
+"We recommend against using bevacizumab in the first-line treatment of newly 
+diagnosed glioblastoma to improve overall survival (Strong recommendation against, 
+High-quality evidence - GRADE 1A)."
+
+Rationale:
+- No OS benefit: HR 0.88 (0.76-1.02), p=0.10 (AVAglio trial)
+- Toxicity: Increased grade ≥3 AEs (66% vs 52%)
+- Evidence: High-quality (two large phase 3 RCTs)
+- Harms outweigh lack of survival benefit
+```
+
+#### Conditional/Weak Recommendation (Grade 2)
+
+**When to Use**:
+- Desirable and undesirable effects closely balanced
+- Low or very low quality evidence
+- Values and preferences: Substantial variability
+- Resource implications: High cost or limited access
+
+**Wording**: "We suggest..." or "Clinicians might..."
+
+**Implications**:
+- Different choices will be appropriate for different patients
+- Shared decision-making essential
+- Policy-making requires substantial debate and stakeholder involvement
+
+**Examples**:
+
+```
+CONDITIONAL RECOMMENDATION FOR (Grade 2):
+
+"We suggest considering maintenance pemetrexed after first-line platinum-pemetrexed 
+chemotherapy for advanced non-squamous NSCLC in patients without disease progression 
+(Conditional recommendation, Moderate-quality evidence - GRADE 2B)."
+
+Rationale:
+- Modest PFS benefit: 4.0 vs 2.0 months (HR 0.62)
+- No OS benefit: 13.9 vs 11.0 months (HR 0.79, p=0.23)
+- Toxicity: Continued chemotherapy burden
+- Quality of life: Trade-off between symptom control and treatment side effects
+- Patient values: Some prioritize time off treatment, others prioritize disease control
+- Shared decision-making essential
+```
+
+```
+CONDITIONAL RECOMMENDATION - EITHER OPTION ACCEPTABLE (Grade 2):
+
+"We suggest either pembrolizumab monotherapy OR pembrolizumab plus platinum-doublet 
+chemotherapy as first-line treatment for PD-L1 ≥50% NSCLC, based on patient 
+preferences and clinical factors (Conditional recommendation, High-quality evidence - 
+GRADE 2A)."
+
+Rationale:
+- Both regimens NCCN Category 1 preferred
+- Monotherapy: Less toxicity, oral vs IV, better quality of life
+- Combination: Higher ORR (48% vs 39%), numerically longer PFS
+- OS: Similar between strategies
+- Patient values: Varies widely (tolerability vs response rate priority)
+```
+
+### Evidence Quality (⊕⊕⊕⊕ to ⊕○○○)
+
+#### High Quality (⊕⊕⊕⊕)
+
+- Further research very unlikely to change confidence in effect estimate
+- Consistent results from well-designed RCTs
+- No serious limitations
+- Direct evidence (target population, intervention, outcomes)
+- Precise estimate (narrow CI)
+
+**Example**: FLAURA trial for osimertinib in EGFR+ NSCLC - Large RCT, consistent results, low risk of bias, direct outcomes
+
+#### Moderate Quality (⊕⊕⊕○)
+
+- Further research likely to impact confidence and may change estimate
+- RCTs with some limitations OR very strong evidence from observational studies
+- Some inconsistency, indirectness, imprecision, or publication bias
+
+**Example**: Single RCT with some limitations, or multiple RCTs with moderate heterogeneity
+
+#### Low Quality (⊕⊕○○)
+
+- Further research very likely to have important impact on confidence in estimate
+- Observational studies OR RCTs with serious limitations
+- Serious issues with consistency, directness, precision, or bias
+
+**Example**: Well-conducted cohort study, or RCT with high attrition and unclear allocation concealment
+
+#### Very Low Quality (⊕○○○)
+
+- Estimate of effect very uncertain
+- Case series, expert opinion, mechanistic reasoning
+- Very serious limitations
+
+**Example**: Retrospective case series, expert consensus without systematic review
+
+## Combining Strength and Quality
+
+### All Nine Possible Combinations
+
+| Evidence Quality | Strong For (↑↑) | Weak For (↑) | Strong Against (↓↓) | Weak Against (↓) |
+|-----------------|----------------|--------------|---------------------|------------------|
+| **High (⊕⊕⊕⊕)** | Grade 1A | Grade 2A | Grade 1A (against) | Grade 2A (against) |
+| **Moderate (⊕⊕⊕○)** | Grade 1B | Grade 2B | Grade 1B (against) | Grade 2B (against) |
+| **Low (⊕⊕○○)** | Grade 1C* | Grade 2C | Grade 1C (against)* | Grade 2C (against) |
+| **Very Low (⊕○○○)** | Grade 1D* | Grade 2D | Grade 1D (against)* | Grade 2D (against) |
+
+*Rare: Strong recommendations usually require at least moderate-quality evidence
+
+### Unusual Combinations (When They Occur)
+
+**Strong Recommendation with Low Quality Evidence (Grade 1C)**
+
+Rare, but can occur when:
+- Large magnitude of effect from observational data (RR >5 or <0.2)
+- Low quality evidence, but clear benefit-harm balance
+- Example: Anticoagulation for atrial fibrillation (before RCTs, strong observational data)
+
+**Weak Recommendation with High Quality Evidence (Grade 2A)**
+
+Occurs when:
+- Benefits and harms closely balanced
+- Patient values highly variable
+- Example: Aspirin for primary prevention in low-risk individuals (benefits small, bleeding risk present, patient values vary)
+
+## Wording Templates
+
+### Strong Recommendations
+
+**FOR (↑↑)**:
+- "We recommend [intervention] for [population]."
+- "Clinicians should [action]."
+- "[Intervention] is recommended."
+
+**AGAINST (↓↓)**:
+- "We recommend against [intervention] for [population]."
+- "Clinicians should not [action]."
+- "[Intervention] is not recommended."
+
+### Conditional/Weak Recommendations
+
+**FOR (↑)**:
+- "We suggest [intervention] for [population]."
+- "Clinicians might consider [action]."
+- "[Intervention] may be considered for selected patients."
+
+**AGAINST (↓)**:
+- "We suggest not using [intervention] for [population]."
+- "Clinicians might avoid [action]."
+- "[Intervention] is generally not recommended."
+
+**EITHER ACCEPTABLE**:
+- "We suggest either [option A] or [option B] based on patient preferences."
+- "Either approach is reasonable."
+
+## Color Coding for Visual Documents
+
+**Strong Recommendations (Green Background)**:
+- RGB(0, 153, 76) or #009954
+- Clear visual priority
+- Use for Grade 1A, 1B
+
+**Conditional Recommendations (Yellow Background)**:
+- RGB(255, 193, 7) or #FFC107
+- Indicates discussion needed
+- Use for Grade 2A, 2B, 2C
+
+**Research/Investigational (Blue Background)**:
+- RGB(33, 150, 243) or #2196F3
+- Clinical trial consideration
+- Insufficient evidence for standard care
+
+**Not Recommended (Red Border/Background)**:
+- RGB(220, 20, 60) or #DC143C
+- Strong recommendation against
+- Evidence of harm or no benefit
+
+## Common Scenarios
+
+### Scenario 1: Strong Evidence, Clear Benefit-Harm Balance
+
+**Example**: Pembrolizumab for PD-L1 ≥50% NSCLC
+
+- Evidence: Large phase 3 RCT (KEYNOTE-024), n=305, well-designed
+- Results: PFS HR 0.50 (0.37-0.68), OS HR 0.60 (0.41-0.89)
+- Toxicity: Lower grade 3-5 AEs than chemotherapy (27% vs 53%)
+- Patient values: Most prioritize efficacy and tolerability
+
+**Recommendation**: STRONG FOR (Grade 1A)
+
+### Scenario 2: Moderate Evidence, Balanced Trade-Offs
+
+**Example**: Adjuvant immunotherapy for resected melanoma
+
+- Evidence: RCT showing relapse-free survival benefit, OS data immature
+- Results: Recurrence risk reduced but ongoing toxicity
+- Toxicity: Immune-related AEs requiring steroids (some severe)
+- Cost: High annual cost for 12 months treatment
+- Patient values: Variable (some prioritize recurrence prevention, others avoid toxicity)
+
+**Recommendation**: CONDITIONAL FOR (Grade 2B)
+
+### Scenario 3: Low Evidence, but Severe Consequence
+
+**Example**: Anticoagulation for prosthetic heart valve
+
+- Evidence: No RCTs (would be unethical), observational data and mechanistic reasoning
+- Consequence: Very high thromboembolic risk without anticoagulation
+- Benefit-harm: Clear despite low quality evidence
+
+**Recommendation**: STRONG FOR (Grade 1C)
+
+### Scenario 4: High Evidence, but Patient Preferences Vary
+
+**Example**: Breast reconstruction after mastectomy
+
+- Evidence: High-quality data on outcomes and satisfaction
+- Trade-offs: Cosmetic benefit vs additional surgery, recovery time
+- Values: Highly personal decision, wide preference variability
+
+**Recommendation**: CONDITIONAL (Grade 2A) - discuss options, patient decides
+
+## Documentation Template
+
+```
+RECOMMENDATION: [State recommendation clearly]
+
+Strength: [STRONG / CONDITIONAL]
+Quality of Evidence: [HIGH / MODERATE / LOW / VERY LOW]
+GRADE: [1A / 1B / 2A / 2B / 2C]
+
+Evidence Summary:
+- Primary study: [Citation]
+- Design: [RCT / Observational / Meta-analysis]
+- Sample size: n = [X]
+- Results: [Primary outcome with effect size, CI, p-value]
+- Quality assessment: [Strengths and limitations]
+
+Benefits:
+- [Quantified benefit 1]
+- [Quantified benefit 2]
+
+Harms:
+- [Quantified harm 1]
+- [Quantified harm 2]
+
+Balance: [Benefits clearly outweigh harms / Close balance requiring discussion / etc.]
+
+Values and Preferences: [Little variability / Substantial variability]
+
+Cost Considerations: [If relevant]
+
+Guideline Concordance:
+- NCCN: [Category and recommendation]
+- ASCO: [Recommendation]
+- ESMO: [Grade and recommendation]
+```
+
+## Quality Checklist
+
+Before finalizing recommendations, verify:
+
+- [ ] Recommendation statement is clear and actionable
+- [ ] Strength is explicitly stated (strong vs conditional)
+- [ ] Quality of evidence is graded (high/moderate/low/very low)
+- [ ] GRADE notation provided (1A, 1B, 2A, 2B, 2C)
+- [ ] Evidence is cited with specific study results
+- [ ] Benefits are quantified (effect sizes with CIs)
+- [ ] Harms are quantified (AE rates)
+- [ ] Balance of benefits/harms is explained
+- [ ] Patient values consideration is addressed (if conditional)
+- [ ] Alternative options are mentioned
+- [ ] Guideline concordance is documented
+- [ ] Special populations are addressed (elderly, renal/hepatic impairment)
+- [ ] Monitoring requirements are specified
+